Lanreotid versus placebo før operation for at forhindre en kirurgisk komplikation kaldet en pancreasfistel
Et randomiseret fase III blindet forsøg med lanreotid til forebyggelse af postoperativ pancreasfistel
This phase III trial compares the effect of using lanreotide before surgery to surgery alone in preventing pancreatic fistulas in patients with pancreatic cancer or a pancreatic lesion that could become cancerous. Lanreotide, a type of somatostatin analog similar to somatostatin (a hormone made by the body), and is used to treat certain types of gastroenteropancreatic neuroendocrine tumors, and carcinoid syndrome. It may help stop the body from making extra amounts of certain hormones, including growth hormone, insulin, glucagon, and hormones that affect digestion. It may also help keep certain types of tumor cells from growing. Patients with pancreatic cancer or pancreatic lesions may undergo surgery to remove parts of the pancreas, also called a distal pancreatectomy. Patients may experience complications after surgery, including pancreatic fistulas. A pancreatic fistula occurs when there is a small leak from the pancreas, causing fluids to collect. This can often lead to infection and other problems. Giving lanreotide before undergoing distal pancreatectomy may be more effective than surgery alone in preventing the development of a pancreatic fistula in patients with pancreatic cancer or a pancreatic lesion that could become cancerous.
Studieoversigt
Status
Status
Betingelser
Betingelser
Intervention / Behandling
Intervention / Behandling
Detaljeret beskrivelse
PRIMARY OBJECTIVE:
I. To compare the incidence of postoperative pancreatic fistula (POPF) occurring within 60 days after surgery in participants randomized to receive preoperative lanreotide versus placebo prior to undergoing distal pancreatectomy for biopsy-proven or suspected neoplasm.
SECONDARY OBJECTIVES:
I. To compare the incidence of International Study Group of Pancreatic Surgery (ISGPS)-defined biochemical leak occurring within 60 days after surgery in participants randomized to receive preoperative lanreotide versus placebo in the subset of participants with a drain placed.
II. To compare the number of postoperative days in the hospital within 60 days after surgery in participants randomized to receive preoperative lanreotide versus placebo.
III. To compare change from baseline in cancer-specific quality of life at 14 and 60 days after surgery, as measured by the European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire (QLQ) Core 30-(C30), in participants randomized to receive preoperative lanreotide versus placebo.
ADDITIONAL OBJECTIVES:
I. To compare change from baseline in pancreatic cancer-specific quality of life and overall health-related quality of life at 14 and 60 days after surgery, as measured by the EORTC QLQ- Pancreatic Cancer 26 (PAN26) and European Quality of Life Five Dimension Five Level (EQ-5D-5L), in participants randomized to receive preoperative lanreotide versus placebo.
II. To compare the proportions of participants with common postoperative sequelae associated with POPF, including ISGPS delayed gastric emptying and ISGPS post pancreatectomy hemorrhage (grades B/C) occurring within 60 days after surgery, in participants randomized to receive preoperative lanreotide versus placebo.
III. To compare time from surgery to initiation of adjuvant chemotherapy among participants with pancreatic ductal adenocarcinoma and planned adjuvant chemotherapy randomized to receive preoperative lanreotide versus placebo.
BANKING OBJECTIVE:
I. To bank blood, pancreas fluid, and tissue specimens for future correlative studies.
OUTLINE: Patients are randomized to 1 of 2 arms.
ARM I: Patients receive lanreotide subcutaneously (SC) over 20 seconds and within 36 hours of planned distal pancreatectomy. Patients also undergo blood sample collection immediately prior to surgery and on post-operative days 1 and 3. Additionally, patients may undergo collection of pancreas fluid on post-operative days 1 and 3.
ARM II: Patients receive saline placebo SC over 20 seconds and within 36 hours of planned distal pancreatectomy. Patients also undergo blood sample collection immediately prior to surgery and post-operatively on days 1 and 3. Additionally, patients may undergo collection of pancreas fluid on post-operative days 1 and 3.
After completion of study treatment, patients are followed up at 4, 8 and 12 months after surgery.
Undersøgelsestype
Undersøgelsestype
Tilmelding (Anslået)
Tilmelding
Fase
Fase
- Fase 3
Kontakter og lokationer
Studiekontakt
Studiekontakt
- Navn: Dana Sparks
- Telefonnummer: 210-614-8808
- E-mail: dsparks@swog.org
Undersøgelse Kontakt Backup
- Navn: Andrea Garcia
- Telefonnummer: 210-614-8808
- E-mail: agarcia@swog.org
Studiesteder
-
-
Alabama
-
Birmingham, Alabama, Forenede Stater, 35233
- Suspenderet
- University of Alabama at Birmingham Cancer Center
-
Daphne, Alabama, Forenede Stater, 36526
- Suspenderet
- Gulf Health Hospitals Inc/Infirmary Cancer Care - Malbis
-
Fairhope, Alabama, Forenede Stater, 36532
- Suspenderet
- Thomas Hospital
-
Mobile, Alabama, Forenede Stater, 36607
- Suspenderet
- Mobile Infirmary Medical Center
-
Saraland, Alabama, Forenede Stater, 36571
- Suspenderet
- Gulf Health Hospitals Inc/Infirmary Cancer Care - Saraland
-
-
Arizona
-
Gilbert, Arizona, Forenede Stater, 85234
- Suspenderet
- Banner MD Anderson Cancer Center
-
-
California
-
Duarte, California, Forenede Stater, 91010
- Suspenderet
- City of Hope Comprehensive Cancer Center
-
La Jolla, California, Forenede Stater, 92093
- Rekruttering
- UC San Diego Moores Cancer Center
-
Kontakt:
- Site Public Contact
- Telefonnummer: 858-822-5354
- E-mail: cancercto@ucsd.edu
-
Ledende efterforsker:
- Andrew M. Lowy
-
Loma Linda, California, Forenede Stater, 92357
- Suspenderet
- Veterans Affairs Loma Linda Healthcare System
-
Los Angeles, California, Forenede Stater, 90033
- Suspenderet
- USC / Norris Comprehensive Cancer Center
-
San Diego, California, Forenede Stater, 92103
- Suspenderet
- UC San Diego Medical Center - Hillcrest
-
-
Delaware
-
Newark, Delaware, Forenede Stater, 19718
- Suspenderet
- Christiana Care Health System-Christiana Hospital
-
Newark, Delaware, Forenede Stater, 19713
- Suspenderet
- Helen F Graham Cancer Center
-
Newark, Delaware, Forenede Stater, 19713
- Suspenderet
- Medical Oncology Hematology Consultants PA
-
Wilmington, Delaware, Forenede Stater, 19801
- Suspenderet
- Christiana Care Health System-Wilmington Hospital
-
-
Florida
-
Ruskin, Florida, Forenede Stater, 33570
- Suspenderet
- Moffitt Cancer Center at SouthShore
-
Tampa, Florida, Forenede Stater, 33612
- Rekruttering
- Moffitt Cancer Center - McKinley Campus
-
Kontakt:
- Site Public Contact
- Telefonnummer: 800-679-0775
- E-mail: ClinicalTrials@moffitt.org
-
Ledende efterforsker:
- Andrew J. Sinnamon
-
Tampa, Florida, Forenede Stater, 33607
- Suspenderet
- Moffitt Cancer Center-International Plaza
-
Tampa, Florida, Forenede Stater, 33612
- Suspenderet
- Moffitt Cancer Center
-
Wesley Chapel, Florida, Forenede Stater, 33544
- Suspenderet
- Moffitt Cancer Center at Wesley Chapel
-
-
Georgia
-
Atlanta, Georgia, Forenede Stater, 30342
- Suspenderet
- Emory Saint Joseph's Hospital
-
Atlanta, Georgia, Forenede Stater, 30308
- Suspenderet
- Emory University Hospital Midtown
-
Atlanta, Georgia, Forenede Stater, 30322
- Suspenderet
- Emory University Hospital/Winship Cancer Institute
-
Atlanta, Georgia, Forenede Stater, 30303
- Suspenderet
- Grady Health System
-
Johns Creek, Georgia, Forenede Stater, 30097
- Suspenderet
- Emory Johns Creek Hospital
-
-
Illinois
-
Chicago, Illinois, Forenede Stater, 60611
- Rekruttering
- Northwestern University
-
Kontakt:
- Site Public Contact
- Telefonnummer: 312-695-1301
- E-mail: cancer@northwestern.edu
-
Ledende efterforsker:
- Akhil Chawla
-
Chicago, Illinois, Forenede Stater, 60612
- Rekruttering
- University of Illinois
-
Ledende efterforsker:
- Aslam Ejaz
-
Kontakt:
- Site Public Contact
- Telefonnummer: 312-355-3046
-
Geneva, Illinois, Forenede Stater, 60134
- Suspenderet
- Northwestern Medicine Cancer Center Delnor
-
Oak Brook, Illinois, Forenede Stater, 60523
- Suspenderet
- Northwestern Medicine Oak Brook
-
Orland Park, Illinois, Forenede Stater, 60462
- Suspenderet
- Northwestern Medicine Orland Park
-
Warrenville, Illinois, Forenede Stater, 60555
- Suspenderet
- Northwestern Medicine Cancer Center Warrenville
-
-
Indiana
-
Indianapolis, Indiana, Forenede Stater, 46202
- Suspenderet
- Indiana University/Melvin and Bren Simon Cancer Center
-
-
Kentucky
-
Lexington, Kentucky, Forenede Stater, 40536
- Rekruttering
- University of Kentucky/Markey Cancer Center
-
Ledende efterforsker:
- Michael J. Cavnar
-
Kontakt:
- Site Public Contact
- Telefonnummer: 859-257-3379
-
-
Louisiana
-
New Orleans, Louisiana, Forenede Stater, 70112
- Suspenderet
- University Medical Center New Orleans
-
-
Maryland
-
Elkton, Maryland, Forenede Stater, 21921
- Suspenderet
- Christiana Care - Union Hospital
-
-
Michigan
-
Ann Arbor, Michigan, Forenede Stater, 48109
- Suspenderet
- University of Michigan Rogel Cancer Center
-
Battle Creek, Michigan, Forenede Stater, 49017
- Suspenderet
- Bronson Battle Creek
-
Grand Rapids, Michigan, Forenede Stater, 49503
- Suspenderet
- Trinity Health Grand Rapids Hospital
-
Grand Rapids, Michigan, Forenede Stater, 49503
- Suspenderet
- Corewell Health Grand Rapids Hospitals - Helen DeVos Children's Hospital
-
Grand Rapids, Michigan, Forenede Stater, 49503
- Suspenderet
- Corewell Health Grand Rapids Hospitals - Butterworth Hospital
-
Muskegon, Michigan, Forenede Stater, 49444
- Suspenderet
- Trinity Health Muskegon Hospital
-
Niles, Michigan, Forenede Stater, 49120
- Suspenderet
- Corewell Health Lakeland Hospitals - Niles Hospital
-
Norton Shores, Michigan, Forenede Stater, 49444
- Suspenderet
- Cancer and Hematology Centers of Western Michigan - Norton Shores
-
Reed City, Michigan, Forenede Stater, 49677
- Suspenderet
- Corewell Health Reed City Hospital
-
Saint Joseph, Michigan, Forenede Stater, 49085
- Suspenderet
- Corewell Health Lakeland Hospitals - Marie Yeager Cancer Center
-
Saint Joseph, Michigan, Forenede Stater, 49085
- Suspenderet
- Corewell Health Lakeland Hospitals - Saint Joseph Hospital
-
Wyoming, Michigan, Forenede Stater, 49519
- Suspenderet
- University of Michigan Health - West
-
-
Minnesota
-
Aitkin, Minnesota, Forenede Stater, 56431
- Suspenderet
- Riverwood Healthcare Center
-
Baxter, Minnesota, Forenede Stater, 56425
- Suspenderet
- Essentia Health - Baxter Clinic
-
Brainerd, Minnesota, Forenede Stater, 56401
- Suspenderet
- Essentia Health Saint Joseph's Medical Center
-
Crosslake, Minnesota, Forenede Stater, 56442
- Suspenderet
- Essentia Health - Saint Joseph's Crosslake Clinic
-
Deer River, Minnesota, Forenede Stater, 56636
- Suspenderet
- Essentia Health - Deer River Clinic
-
Detroit Lakes, Minnesota, Forenede Stater, 56501
- Suspenderet
- Essentia Health Saint Mary's - Detroit Lakes Clinic
-
Duluth, Minnesota, Forenede Stater, 55805
- Suspenderet
- Essentia Health Saint Mary's Medical Center
-
Duluth, Minnesota, Forenede Stater, 55805
- Suspenderet
- Miller-Dwan Hospital
-
Duluth, Minnesota, Forenede Stater, 55805
- Suspenderet
- Essentia Health Cancer Center
-
Ely, Minnesota, Forenede Stater, 55731
- Suspenderet
- Essentia Health - Ely Clinic
-
Fosston, Minnesota, Forenede Stater, 56542
- Suspenderet
- Essentia Health - Fosston
-
Hibbing, Minnesota, Forenede Stater, 55746
- Suspenderet
- Essentia Health Hibbing Clinic
-
International Falls, Minnesota, Forenede Stater, 56649
- Suspenderet
- Essentia Health - International Falls Clinic
-
Moose Lake, Minnesota, Forenede Stater, 55767
- Suspenderet
- Essentia Health - Moose Lake Clinic
-
Park Rapids, Minnesota, Forenede Stater, 56470
- Suspenderet
- Essentia Health - Park Rapids
-
Pequot Lakes, Minnesota, Forenede Stater, 56472
- Suspenderet
- Essentia Health - Saint Joseph's Pequot Lakes Clinic
-
Pine River, Minnesota, Forenede Stater, 56474
- Suspenderet
- Essentia Health - Saint Joseph's Pine River Clinic
-
Sandstone, Minnesota, Forenede Stater, 55072
- Suspenderet
- Essentia Health Sandstone
-
Staples, Minnesota, Forenede Stater, 56479
- Suspenderet
- Essentia Health - Saint Joseph's Staples Clinic
-
Virginia, Minnesota, Forenede Stater, 55792
- Suspenderet
- Essentia Health Virginia Clinic
-
-
Missouri
-
Farmington, Missouri, Forenede Stater, 63640
- Rekruttering
- Parkland Health Center - Farmington
-
Ledende efterforsker:
- Bryan A. Faller
-
Kontakt:
- Site Public Contact
- Telefonnummer: 314-996-5569
-
Sainte Genevieve, Missouri, Forenede Stater, 63670
- Rekruttering
- Sainte Genevieve County Memorial Hospital
-
Ledende efterforsker:
- Bryan A. Faller
-
Kontakt:
- Site Public Contact
- Telefonnummer: 314-996-5569
-
St Louis, Missouri, Forenede Stater, 63131
- Rekruttering
- Missouri Baptist Medical Center
-
Ledende efterforsker:
- Bryan A. Faller
-
Kontakt:
- Site Public Contact
- Telefonnummer: 314-996-5569
-
Sullivan, Missouri, Forenede Stater, 63080
- Rekruttering
- Missouri Baptist Sullivan Hospital
-
Ledende efterforsker:
- Bryan A. Faller
-
Kontakt:
- Site Public Contact
- Telefonnummer: 314-996-5569
-
Sunset Hills, Missouri, Forenede Stater, 63127
- Rekruttering
- BJC Outpatient Center at Sunset Hills
-
Ledende efterforsker:
- Bryan A. Faller
-
Kontakt:
- Site Public Contact
- Telefonnummer: 314-996-5569
-
-
Nebraska
-
Omaha, Nebraska, Forenede Stater, 68198
- Suspenderet
- University of Nebraska Medical Center
-
-
Nevada
-
Reno, Nevada, Forenede Stater, 89502
- Suspenderet
- Renown Regional Medical Center
-
-
New Jersey
-
Livingston, New Jersey, Forenede Stater, 07039
- Suspenderet
- Saint Barnabas Medical Center
-
New Brunswick, New Jersey, Forenede Stater, 08903
- Suspenderet
- Rutgers Cancer Institute of New Jersey
-
-
New Mexico
-
Albuquerque, New Mexico, Forenede Stater, 87106
- Suspenderet
- University of New Mexico Cancer Center
-
-
New York
-
Rochester, New York, Forenede Stater, 14642
- Suspenderet
- University of Rochester
-
Syracuse, New York, Forenede Stater, 13210
- Suspenderet
- State University of New York Upstate Medical University
-
-
North Carolina
-
Charlotte, North Carolina, Forenede Stater, 28203
- Suspenderet
- Carolinas Medical Center/Levine Cancer Institute
-
Concord, North Carolina, Forenede Stater, 28025
- Suspenderet
- Atrium Health Cabarrus/LCI-Concord
-
-
North Dakota
-
Fargo, North Dakota, Forenede Stater, 58103
- Suspenderet
- Essentia Health Cancer Center-South University Clinic
-
Fargo, North Dakota, Forenede Stater, 58122
- Suspenderet
- Sanford Roger Maris Cancer Center
-
Fargo, North Dakota, Forenede Stater, 58122
- Suspenderet
- Sanford Broadway Medical Center
-
Jamestown, North Dakota, Forenede Stater, 58401
- Suspenderet
- Essentia Health - Jamestown Clinic
-
-
Ohio
-
Cincinnati, Ohio, Forenede Stater, 45219
- Suspenderet
- University of Cincinnati Cancer Center-UC Medical Center
-
Columbus, Ohio, Forenede Stater, 43210
- Suspenderet
- Ohio State University Comprehensive Cancer Center
-
West Chester, Ohio, Forenede Stater, 45069
- Suspenderet
- University of Cincinnati Cancer Center-West Chester
-
-
Pennsylvania
-
Allentown, Pennsylvania, Forenede Stater, 18104
- Rekruttering
- Saint Luke's Cancer Center - Allentown
-
Kontakt:
- Site Public Contact
- Telefonnummer: 610-776-4714
-
Ledende efterforsker:
- Darius C. Desai
-
Bethlehem, Pennsylvania, Forenede Stater, 18015
- Rekruttering
- Saint Luke's University Hospital-Bethlehem Campus
-
Kontakt:
- Site Public Contact
- Telefonnummer: 484-503-4151
-
Ledende efterforsker:
- Darius C. Desai
-
Chadds Ford, Pennsylvania, Forenede Stater, 19317
- Suspenderet
- Christiana Care Health System-Concord Health Center
-
Easton, Pennsylvania, Forenede Stater, 18045
- Rekruttering
- Saint Luke's Hospital-Anderson Campus
-
Kontakt:
- Site Public Contact
- Telefonnummer: 888-823-5923
- E-mail: ctsucontact@westat.com
-
Ledende efterforsker:
- Darius C. Desai
-
Quakertown, Pennsylvania, Forenede Stater, 18951
- Rekruttering
- Saint Luke's Hospital - Upper Bucks Campus
-
Kontakt:
- Site Public Contact
- Telefonnummer: 610-776-4714
-
Ledende efterforsker:
- Darius C. Desai
-
Stroudsburg, Pennsylvania, Forenede Stater, 18360
- Rekruttering
- Saint Luke's Hospital - Monroe Campus
-
Kontakt:
- Site Public Contact
- Telefonnummer: 888-823-5923
- E-mail: ctsucontact@westat.com
-
Ledende efterforsker:
- Darius C. Desai
-
Wilkes-Barre, Pennsylvania, Forenede Stater, 18711
- Suspenderet
- Geisinger Wyoming Valley/Henry Cancer Center
-
-
South Dakota
-
Sioux Falls, South Dakota, Forenede Stater, 57104
- Suspenderet
- Sanford Cancer Center Oncology Clinic
-
Sioux Falls, South Dakota, Forenede Stater, 57117-5134
- Suspenderet
- Sanford USD Medical Center - Sioux Falls
-
-
Tennessee
-
Knoxville, Tennessee, Forenede Stater, 37920
- Suspenderet
- University of Tennessee - Knoxville
-
Memphis, Tennessee, Forenede Stater, 38120
- Suspenderet
- Baptist Memorial Hospital and Cancer Center-Memphis
-
-
Vermont
-
Burlington, Vermont, Forenede Stater, 05405
- Suspenderet
- University of Vermont and State Agricultural College
-
Burlington, Vermont, Forenede Stater, 05401
- Suspenderet
- University of Vermont Medical Center
-
-
Virginia
-
Richmond, Virginia, Forenede Stater, 23235
- Rekruttering
- VCU Massey Cancer Center at Stony Point
-
Kontakt:
- Site Public Contact
- E-mail: ctoclinops@vcu.edu
-
Ledende efterforsker:
- Leopoldo J. Fernandez
-
Richmond, Virginia, Forenede Stater, 23298
- Rekruttering
- VCU Massey Comprehensive Cancer Center
-
Ledende efterforsker:
- Leopoldo J. Fernandez
-
Kontakt:
- Site Public Contact
- Telefonnummer: 804-628-6430
- E-mail: CTOclinops@vcu.edu
-
Roanoke, Virginia, Forenede Stater, 24033
- Suspenderet
- Carilion Roanoke Memorial Hospital
-
Winchester, Virginia, Forenede Stater, 22601
- Suspenderet
- Valley Health / Winchester Medical Center
-
-
Washington
-
Seattle, Washington, Forenede Stater, 98195
- Suspenderet
- University of Washington Medical Center - Montlake
-
Seattle, Washington, Forenede Stater, 98109
- Suspenderet
- Fred Hutchinson Cancer Center
-
-
Wisconsin
-
Ashland, Wisconsin, Forenede Stater, 54806
- Suspenderet
- Northwest Wisconsin Cancer Center
-
Ashland, Wisconsin, Forenede Stater, 54806
- Suspenderet
- Duluth Clinic Ashland
-
Hayward, Wisconsin, Forenede Stater, 54843
- Suspenderet
- Essentia Health-Hayward Clinic
-
Hayward, Wisconsin, Forenede Stater, 54843
- Suspenderet
- Tamarack Health Hayward Medical Center
-
Marshfield, Wisconsin, Forenede Stater, 54449
- Rekruttering
- Marshfield Medical Center-Marshfield
-
Kontakt:
- Site Public Contact
- Telefonnummer: 800-782-8581
- E-mail: oncology.clinical.trials@marshfieldresearch.org
-
Ledende efterforsker:
- Jessica A. Wernberg
-
Mukwonago, Wisconsin, Forenede Stater, 53149
- Suspenderet
- ProHealth D N Greenwald Center
-
Oconomowoc, Wisconsin, Forenede Stater, 53066
- Suspenderet
- ProHealth Oconomowoc Memorial Hospital
-
Spooner, Wisconsin, Forenede Stater, 54801
- Suspenderet
- Essentia Health-Spooner Clinic
-
Superior, Wisconsin, Forenede Stater, 54880
- Suspenderet
- Essentia Health Saint Mary's Hospital - Superior
-
Waukesha, Wisconsin, Forenede Stater, 53188
- Suspenderet
- ProHealth Waukesha Memorial Hospital
-
Waukesha, Wisconsin, Forenede Stater, 53188
- Suspenderet
- UW Cancer Center at ProHealth Care
-
-
Deltagelseskriterier
Berettigelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Inclusion Criteria:
-
Participants must have histologically or radiographically confirmed diagnosis of pancreatic cancer or a pancreatic lesion with malignant potential
-
Participants must have an elective distal pancreatectomy planned to occur within 60 days after registration/randomization date
-
Participants must not have a known history of a prior diagnosis of malabsorption syndrome
-
Participants must not have been treated with any somatostatin analogue within 180 days prior to registration/randomization
-
Participants must not have been treated with radiation therapy for their pancreas malignancy at any time prior to registration/randomization
-
Participants must not have been treated with peptide receptor radionuclide therapy (PRRT) at any time prior to registration/randomization
-
Participants must be ≥ 18 years old
-
Participants must have a complete documented medical history and physical exam within 28 days prior to registration/randomization
-
Participants must have a creatinine ≤ the institutional upper limit of normal (IULN) OR a measured OR calculated creatinine clearance ≥ 50 mL/min using the following Cockcroft -Gault formula within 60 days prior to registration/randomization
-
Participants must complete a pre-registration screening to identify any of the medications below, allowing the study team and treating physician to develop a monitoring plan as needed. Participants taking medications with known interactions with lanreotide may remain eligible if appropriate monitoring and management are in place. These medications include:
- Diabetes medications (insulin or oral hypoglycemics): Blood sugar will be monitored, and medication dose adjustments made as needed
- Cyclosporine: Dosage adjustments may be required to maintain therapeutic levels
- Bromocriptine: Dose adjustments may be considered to account for absorption changes
- Heart medications (e.g., beta blockers): Heart rate will be monitored, and medication doses adjusted if necessary
- CYP3A4-metabolized medications: Dose adjustments may be considered to avoid increased exposure
-
In the opinion of the treating surgeon, based on preoperative data, the participant must not require a modified Appleby-type procedure (distal pancreatectomy with celiac axis resection) or multivisceral resection (e.g., stomach, colon, etc.) at the time of distal pancreatectomy
- NOTE: planned removal of the gallbladder or spleen at the time of distal pancreatectomy is not considered multivisceral resection and is permissible
-
In the opinion of the treating surgeon, based on preoperative data, the participant must not require a tumor enucleation
-
Participants must not have moderate to severe hepatic impairment as defined by liver enzyme elevation more than 5 times the institutional upper limit of normal (either aspartate aminotransferase [AST] > 190 U/L or alanine aminotransferase [ALT] > 320 U/L) within 60 days prior to registration/randomization. Transient elevation at the time of screening that resolves prior to study enrollment is acceptable
-
Participants must not be pregnant or nursing (nursing includes breast milk fed to an infant by any means, including from the breast, milk expressed by hand, or pumped)
-
Individuals who are of reproductive potential must have agreed to use an effective contraceptive method during the whole period of the study and for three months after the study drug administration, with details provided as a part of the consent process. A person who has had menses at any time in the preceding 12 consecutive months or who has semen likely to contain sperm is considered to be of "reproductive potential." In addition to routine contraceptive methods, "effective contraception" also includes refraining from sexual activity that might result in pregnancy and surgery intended to prevent pregnancy (or with a side-effect of pregnancy prevention) including hysterectomy, bilateral oophorectomy, bilateral tubal ligation/occlusion, and vasectomy with testing showing no sperm in the semen
-
Participants must be offered the opportunity to participate in specimen banking
-
Participants who can complete EORTC QLQ-C30, EORTC QLQ-PAN26, and EQ-5D-5L forms in English or Spanish, must be offered the opportunity to participate in the quality-of-life study
-
NOTE: As a part of the OPEN registration process, the treating institution's identity is provided in order to ensure that the current (within 365 days) date of institutional review board approval for this study has been entered in the system.
-
Participants must be informed of the investigational nature of this study and must sign and give informed consent in accordance with institutional and federal guidelines
-
For participants with impaired decision-making capabilities, legally authorized representatives may sign and give informed consent on behalf of study participants in accordance with applicable federal, local, and Central Institutional Review Board (CIRB) regulations
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Forebyggelse
- Tildeling: Randomiseret
- Interventionel model: Parallel tildeling
- Maskning: Dobbelt
Antal våben
Våben og indgreb
Deltagergruppe / ArmDeltagergruppe / Arm |
Intervention / BehandlingIntervention / Behandling |
|---|---|
|
Eksperimentel: Arm I (lanreotide, distal pancreatectomy)
Patients receive lanreotide SC over 20 seconds and within 36 hours of planned distal pancreatectomy. Patients also undergo blood sample collection immediately prior to surgery and on post-operative days 1 and 3. Additionally, patients may undergo collection of pancreas fluid on post-operative days 1 and 3. |
Ancillary studies Undergo blood sample and pancreas fluid collection
Andre navne:
Undergo distal pancreatectomy Given SC
Andre navne:
|
|
Placebo komparator: Arm II (saline placebo, distal pancreatectomy)
Patients receive saline placebo SC over 20 seconds and within 36 hours of planned distal pancreatectomy. Patients also undergo blood sample collection immediately prior to surgery and post-operatively on days 1 and 3. Additionally, patients may undergo collection of pancreas fluid on post-operative days 1 and 3. |
Ancillary studies Undergo blood sample and pancreas fluid collection
Andre navne:
Undergo distal pancreatectomy Given SC
Andre navne:
|
Hvad måler undersøgelsen?
Primære resultatmål
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Incidence of postoperative pancreatic fistula (POPF)
Tidsramme: Up to 60 days after distal pancreatectomy
|
POPF will be assessed using the 2016 International Study Group for Pancreas Surgery (ISGPS). Incidence rates of POPF in each treatment arm will be described, and treatment arm differences assessed via logistic regression model with adjustment for stratification factor. |
Up to 60 days after distal pancreatectomy
|
Sekundære resultatmål
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Incidence of biochemical leak (BL)
Tidsramme: Up to 60 days after distal pancreatectomy
|
BL will be defined by the ISGPS as a peritoneal drain amylase greater than three times the upper limit of the institutional normal serum amylase without an effect on clinical management or duration of hospital stay. BL will only be measured in those who had a peritoneal drain placed. Treatment arm differences will be assessed via logistic regression model with adjustment for stratification factor. |
Up to 60 days after distal pancreatectomy
|
|
Number of post-operation hospital days
Tidsramme: From the time of surgery up to 60 days after distal pancreatectomy
|
Mean hospital length of stay will be compared according to treatment arm via linear regression model with adjustment for stratification factor. |
From the time of surgery up to 60 days after distal pancreatectomy
|
|
Change in overall quality of life (QOL)
Tidsramme: At baseline and at 14 and 60 days after surgery
|
Assessed using the European Organization for Research and Treatment of Cancer (EORTC) Quality of Life (QLQ) Core 30 (C30). Treatment arm differences in EORTC QLQ-C30 changes will be assessed by repeated measures linear regression model as a function of randomization assignment, baseline score, stratification factor, and visit. Robust standard errors will be estimated via generalized estimating equations to adjust for correlation between repeated outcome measures. |
At baseline and at 14 and 60 days after surgery
|
Andre resultatmål
Andre resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Changes in pancreatic specific QOL
Tidsramme: At baseline and up to 60 days after distal pancreatectomy
|
Will be assessed using EORTC QLQ- Pancreatic Cancer 26. Treatment arm differences in changes from baseline will be assessed by repeated measures linear regression model as a function of randomization assignment, baseline score, stratification factor, and visit. Robust standard errors will be estimated via generalized estimating equations to adjust for correlation between repeated outcome measures. |
At baseline and up to 60 days after distal pancreatectomy
|
|
Change in health-related QOL
Tidsramme: At baseline and up to 60 days after distal pancreatectomy
|
Will be assessed using the European Quality of Life Five Dimension Five Level scale. Treatment arm differences in changes from baseline will be assessed by repeated measures linear regression model as a function of randomization assignment, baseline score, stratification factor, and visit. Robust standard errors will be estimated via generalized estimating equations to adjust for correlation between repeated outcome measures. |
At baseline and up to 60 days after distal pancreatectomy
|
|
Delayed gastric emptying (DGE)
Tidsramme: Up to 60 days after distal pancreatectomy
|
DGE will be defined by the ISGPS as reinsertion or persistence of a nasogastric tube after postoperative day (POD) 3 or inability to tolerate solid oral intake by POD 7. Treatment arm differences in the proportion of participants with DGE will be assessed via logistic regression model with adjustment for stratification factor. |
Up to 60 days after distal pancreatectomy
|
|
Incidence of grades B/C post-pancreatectomy hemorrhage (PPH)
Tidsramme: Up to 60 days after distal pancreatectomy
|
PPH will be defined by the ISGPS as postoperative intra- or extra-luminal hemorrhage requiring transfusion of fluid or blood, intensive care unit transfer, therapeutic endoscopy, endovascular embolization, or reoperation. Treatment arm differences in the proportion of participants with PPH will be assessed via logistic regression model with adjustment for stratification factor. |
Up to 60 days after distal pancreatectomy
|
|
Time to initiation of adjuvant chemotherapy
Tidsramme: From date of surgery to date of first dose of adjuvant chemotherapy up to 60 days after distal pancreatectomy
|
Distributions of time from surgery to initiation of adjuvant chemotherapy, among participants with planned adjuvant chemotherapy, in each arm will be estimated via cumulative incidence and compared using the stratified log-rank test. |
From date of surgery to date of first dose of adjuvant chemotherapy up to 60 days after distal pancreatectomy
|
|
Incidence of nausea and vomiting
Tidsramme: Up to 60 days after distal pancreatectomy
|
Proportions of participants with any nausea/vomiting will be compared between treatment arms via Fisher's exact test. |
Up to 60 days after distal pancreatectomy
|
Samarbejdspartnere og efterforskere
Sponsor
Sponsor
Samarbejdspartnere
Samarbejdspartnere
Efterforskere
Efterforskere
- Ledende efterforsker: Jonathan G Sham, SWOG Cancer Research Network
Publikationer og nyttige links
Datoer for undersøgelser
Studer store datoer
Studiestart (Faktiske)
Studiestart
Primær færdiggørelse (Anslået)
Primær færdiggørelse
Studieafslutning (Anslået)
Studieafslutning
Datoer for studieregistrering
Først indsendt
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Først opslået
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering sendt
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Yderligere relevante MeSH-vilkår
- Sygdomme i det endokrine system
- Neoplasmer efter sted
- Neoplasmer
- Neoplasmer i fordøjelsessystemet
- Sygdomme i fordøjelsessystemet
- Neoplasmer i endokrine kirtler
- Pancreassygdomme
- Bugspytkirtel neoplasmer
- Farmaceutiske præparater
- Undersøgelsesteknikker
- Kliniske laboratorieteknikker
- Diagnostiske teknikker og procedurer
- Diagnose
- Uorganiske kemikalier
- Klorforbindelser
- Krystalloidopløsninger
- Isotoniske løsninger
- Løsninger
- Natriumforbindelser
- Chlorider
- Hydrochlorsyre
- Salinopløsning
- Håndtering af eksemplar
- Natriumchlorid
- Lanreotid
Andre undersøgelses-id-numre
Andre undersøgelses-id-numre
- S2408
- UG1CA189974 (U.S. NIH-bevilling/kontrakt)
- NCI-2024-08361 (Registry Identifier: CTRP (Clinical Trial Reporting Program))
- SWOG-S2408 (Anden identifikator: DCP)
- S2408 (Anden identifikator: SWOG)
- S2408 (Anden identifikator: CTEP)
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
produkt fremstillet i og eksporteret fra U.S.A.
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .